BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 37277530)

  • 1. An allosteric pan-TEAD inhibitor blocks oncogenic YAP/TAZ signaling and overcomes KRAS G12C inhibitor resistance.
    Hagenbeek TJ; Zbieg JR; Hafner M; Mroue R; Lacap JA; Sodir NM; Noland CL; Afghani S; Kishore A; Bhat KP; Yao X; Schmidt S; Clausen S; Steffek M; Lee W; Beroza P; Martin S; Lin E; Fong R; Di Lello P; Kubala MH; Yang MN; Lau JT; Chan E; Arrazate A; An L; Levy E; Lorenzo MN; Lee HJ; Pham TH; Modrusan Z; Zang R; Chen YC; Kabza M; Ahmed M; Li J; Chang MT; Maddalo D; Evangelista M; Ye X; Crawford JJ; Dey A
    Nat Cancer; 2023 Jun; 4(6):812-828. PubMed ID: 37277530
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hippo pathway inhibition by blocking the YAP/TAZ-TEAD interface: a patent review.
    Crawford JJ; Bronner SM; Zbieg JR
    Expert Opin Ther Pat; 2018 Dec; 28(12):867-873. PubMed ID: 30482112
    [No Abstract]   [Full Text] [Related]  

  • 3. Discovery of a cryptic site at the interface 2 of TEAD - Towards a new family of YAP/TAZ-TEAD inhibitors.
    Sturbaut M; Bailly F; Coevoet M; Sileo P; Pugniere M; Liberelle M; Magnez R; Thuru X; Chartier-Harlin MC; Melnyk P; Gelin M; Allemand F; Guichou JF; Cotelle P
    Eur J Med Chem; 2021 Dec; 226():113835. PubMed ID: 34509860
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Allosteric Modulation of the YAP/TAZ-TEAD Interaction by Palmitoylation and Small-Molecule Inhibitors.
    Mills KR; Misra J; Torabifard H
    J Phys Chem B; 2024 Apr; 128(16):3795-3806. PubMed ID: 38606592
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TEAD Inhibition Overcomes YAP1/TAZ-Driven Primary and Acquired Resistance to KRASG12C Inhibitors.
    Edwards AC; Stalnecker CA; Jean Morales A; Taylor KE; Klomp JE; Klomp JA; Waters AM; Sudhakar N; Hallin J; Tang TT; Olson P; Post L; Christensen JG; Cox AD; Der CJ
    Cancer Res; 2023 Dec; 83(24):4112-4129. PubMed ID: 37934103
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vestigial-like family member 3 (VGLL3), a cofactor for TEAD transcription factors, promotes cancer cell proliferation by activating the Hippo pathway.
    Hori N; Okada K; Takakura Y; Takano H; Yamaguchi N; Yamaguchi N
    J Biol Chem; 2020 Jun; 295(26):8798-8807. PubMed ID: 32385107
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Novel Irreversible TEAD Inhibitor, SWTX-143, Blocks Hippo Pathway Transcriptional Output and Causes Tumor Regression in Preclinical Mesothelioma Models.
    Hillen H; Candi A; Vanderhoydonck B; Kowalczyk W; Sansores-Garcia L; Kesikiadou EC; Van Huffel L; Spiessens L; Nijs M; Soons E; Haeck W; Klaassen H; Smets W; Spieser SA; Marchand A; Chaltin P; Ciesielski F; Debaene F; Chen L; Kamal A; Gwaltney SL; Versele M; Halder GA
    Mol Cancer Ther; 2024 Jan; 23(1):3-13. PubMed ID: 37748190
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The PDZ-binding motif of Yes-associated protein is required for its co-activation of TEAD-mediated CTGF transcription and oncogenic cell transforming activity.
    Shimomura T; Miyamura N; Hata S; Miura R; Hirayama J; Nishina H
    Biochem Biophys Res Commun; 2014 Jan; 443(3):917-23. PubMed ID: 24380865
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of Quinolinols as Activators of TEAD-Dependent Transcription.
    Pobbati AV; Mejuch T; Chakraborty S; Karatas H; Bharath SR; Guéret SM; Goy PA; Hahne G; Pahl A; Sievers S; Guccione E; Song H; Waldmann H; Hong W
    ACS Chem Biol; 2019 Dec; 14(12):2909-2921. PubMed ID: 31742995
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of YAP/TAZ-TEAD activity induces cytotrophoblast differentiation into syncytiotrophoblast in human trophoblast.
    Mizutani T; Orisaka M; Miyazaki Y; Morichika R; Uesaka M; Miyamoto K; Yoshida Y
    Mol Hum Reprod; 2022 Sep; 28(10):. PubMed ID: 35993908
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A combat with the YAP/TAZ-TEAD oncoproteins for cancer therapy.
    Pobbati AV; Hong W
    Theranostics; 2020; 10(8):3622-3635. PubMed ID: 32206112
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SS18-SSX-Dependent YAP/TAZ Signaling in Synovial Sarcoma.
    Isfort I; Cyra M; Elges S; Kailayangiri S; Altvater B; Rossig C; Steinestel K; Grünewald I; Huss S; Eßeling E; Mikesch JH; Hafner S; Simmet T; Wozniak A; Schöffski P; Larsson O; Wardelmann E; Trautmann M; Hartmann W
    Clin Cancer Res; 2019 Jun; 25(12):3718-3731. PubMed ID: 30814111
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of the YAP/TAZ-TEAD Transcriptional Complex in the Metabolic Control of TRAIL Sensitivity by the Mevalonate Pathway in Cancer Cells.
    El Yousfi Y; Mora-Molina R; López-Rivas A; Yerbes R
    Cells; 2023 Sep; 12(19):. PubMed ID: 37830584
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hippo signaling effectors YAP and TAZ induce Epstein-Barr Virus (EBV) lytic reactivation through TEADs in epithelial cells.
    Van Sciver N; Ohashi M; Pauly NP; Bristol JA; Nelson SE; Johannsen EC; Kenney SC
    PLoS Pathog; 2021 Aug; 17(8):e1009783. PubMed ID: 34339458
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction of AP-1 by YAP/TAZ contributes to cell proliferation and organ growth.
    Koo JH; Plouffe SW; Meng Z; Lee DH; Yang D; Lim DS; Wang CY; Guan KL
    Genes Dev; 2020 Jan; 34(1-2):72-86. PubMed ID: 31831627
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic targeting of TEAD transcription factors in cancer.
    Pobbati AV; Kumar R; Rubin BP; Hong W
    Trends Biochem Sci; 2023 May; 48(5):450-462. PubMed ID: 36709077
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting TEAD-ious resistance.
    Ott CA; Aplin AE
    Trends Cancer; 2023 Oct; 9(10):780-781. PubMed ID: 37543514
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protein-Protein Interaction Disruptors of the YAP/TAZ-TEAD Transcriptional Complex.
    Pobbati AV; Rubin BP
    Molecules; 2020 Dec; 25(24):. PubMed ID: 33352993
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Progress with YAP/TAZ-TEAD inhibitors: a patent review (2018-present).
    Zagiel B; Melnyk P; Cotelle P
    Expert Opin Ther Pat; 2022 Aug; 32(8):899-912. PubMed ID: 35768160
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structure-Based Design of Y-Shaped Covalent TEAD Inhibitors.
    Lu W; Fan M; Ji W; Tse J; You I; Ficarro SB; Tavares I; Che J; Kim AY; Zhu X; Boghossian A; Rees MG; Ronan MM; Roth JA; Hinshaw SM; Nabet B; Corsello SM; Kwiatkowski N; Marto JA; Zhang T; Gray NS
    J Med Chem; 2023 Apr; 66(7):4617-4632. PubMed ID: 36946421
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.